dotMD.com
✓ Translated by DotMD AI Clinical Council Source: Journal of clinical pharmacology • Randomized Controlled Trial
Plain-English Research Story • 8th-Grade Reading Level

Can This Approach Help? Inside the Latest Research on Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the

Both reached C(max) ~1.5 hours later with liraglutide.

Original Paper Title: “Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug” (Journal of clinical pharmacology, 2011-12-15)

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 21
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: Both reached C(max) ~1.5 hours later with liraglutide.
  • Who Was Studied: Randomized Controlled Trial published in Journal of clinical pharmacology following 21 real-world participants.
  • Strength of the Evidence: Earned a 88/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

Liraglutide is a once-daily human GLP-1 analog for treatment of type 2 diabetes. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in Journal of clinical pharmacology conducted a randomized controlled trial evaluating 21 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

Both reached C(max) ~1.5 hours later with liraglutide. No clinically relevant reduction in bioavailability of ethinyl estradiol/levonorgestrel occurred. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in Journal of clinical pharmacology (2011-12-15) • Study Design: Randomized Controlled Trial • Participants: N = 21 • Biostatistical Rigor Score: 88/100. Primary Takeaway: Both reached C(max) ~1.5 hours later with liraglutide.

Study Limitations & Caveats Before You Act

While this randomized controlled trial scored 88/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug”
Published in Journal of clinical pharmacology (2011-12-15) • PMID/ID: 21228406

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 21228406: Can This Approach Help? Inside the Latest Research on Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the

3 of 3 Free Questions Remaining